CA2110291C|838 857|are preferred. In a more
CA2110291C|867 884|embodiment, dextran
CA2110291C|956 962|In a more
CA2117257C|78 91|pad impregnated
CA2119782C|404 418|of H and a linear or
CA2119782C|525 528|H and
CA2129897C|0 11|Coa-it and paf
CA2144312C|242 273|; and 1,3,5,7 nonatetraenedioic acid
CA2144312C|274 300|; 2,5,8 decatrienedioic acid; 3
CA2144312C|302 327|6 dodecadienedioic acid; 3,13
CA2144312C|429 461|acids and certain of their derivatives
CA2155014C|380 397|to the corresponding
CA2155014C|493 504|H, C1-C6 alkyl
CA2155014C|506 520|C2-C6 alkenyl, C2
CA2155014C|521 541|-C6 alkynyl, monocyclic
CA2156289C|359 409|4-dimethylaminobutanoyl)-1,2-O-dioleylgycerol, 3-O-(
CA2156289C|411 469|-dimethylamino-ethyl)carbamoyl-1,2-O-dioleylglycerol, 3-O-(2
CA2156289C|471 527|diethylaminoethyl) carbamoyl-1,2-O-dioleylgycerol, or 2-O-(2
CA2157128C|228 240|, R2 represents
CA2157128C|264 281|group, R3 represents
CA2157128C|307 319|C1-C6 alkyl, C1
CA2157128C|321 329|C6 alkoxy,
CA2157792C|27 49|beta-alanine derivatives
CA2158610C|218 221|, C=O
CA2168021C|293 302|, C1-6alkyl
CA2168021C|687 704|-6alkyloxycarbonyl
CA2168021C|785 796|heterocyclic
CA2173208C|0 20|Levobupivacaine useful
CA2173839C|216 228|dosages or over
CA2175372C|358 381|-6alkynyl; C3-6cycloalkyl
CA2175372C|467 471|halo,
CA2183549C|0 17|Acidified nitrite as
CA2187449C|0 29|Anti-cancer compounds containing
CA2187449C|115 134|C1-4 alkyl, C1-4 alkoxy
CA2187449C|157 168|4 fluoroalkyl
CA2187449C|169 188|; wherein R2 is hydrogen
CA2187449C|216 239|alkynyl, C2-4 hydroxyalkyl
CA2187449C|262 273|-4 cyanoalkyl
